February 4, 2026
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with fulvestrant, for human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







